Results 41 to 50 of about 67,047,750 (228)

Stress Testing in Heart Failure with Preserved Ejection Fraction

, 2021
Exertional dyspnea is the most common symptom in patients with heart failure with preserved ejection fraction; however, it is not specific to this disease.
심지영
core   +1 more source

Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction

Frontiers in Cardiovascular Medicine, 2021
Cardiovascular diseases are the leading cause of mortality in the world. Heart failure with preserved ejection fraction (HFpEF) accounts for about half of all heart failure.
Chen Chi, Yifan Liu, Yawei Xu, Dachun Xu
doaj   +1 more source

Insights Into Myocardial Oxygenation and Cardiovascular Magnetic Resonance Tissue Biomarkers in Heart Failure With Preserved Ejection Fraction. [PDF]

, 2022
BACKGROUND The pathophysiology of heart failure with preserved ejection fraction is not well understood, but evidence strongly suggests involvement of microvascular dysfunction.
Jung, Bernd, Giannetti, Nadia, Guensch, Dominik P., von Tengg-Kobligk, Hendrik, Eberle, Balthasar, Friedrich, Matthias G, Fischer, Kady, King, Iman   +7 more
core   +1 more source

The clinical characteristics of acute heart failure patients with mid-range ejection fraction in Turkey: A subgroup analysis from journey HF-TR study

International Journal of the Cardiovascular Academy, 2020
Background: Heart failure (HF) is a clinical syndrome characterized with a wide spectrum of left ventricular (LV) structural and functional abnormalities.
Umit Yasar Sinan, Dogac Caglar Gurbuz, Oguzhan Celik, Huseyin Altug Cakmak, Salih Kilic, Sinan Inci, Gulay Gok, Mehmet Serdar Kucukokglu, Mehdi Zoghi   +8 more
doaj   +1 more source

Approach to the Treatment of Heart Failure With Preserved Ejection Fraction and Mid- Range Ejection Fraction [PDF]

, 2017
In this article we discuss the treatment of heart failure (HF) with preserved ejection fraction (HFpEF) and of HF with mid-range ejection fraction (HFmrEF) as has received considerable interest since the publciation of the 2016 European Society of ...
Andrew JS Coats, Ewa A Jankowska, Stefan D Anker   +2 more
core   +1 more source

Position of Patients with Mid-Range Ejection Fraction in the General Chronic Heart Failure Population

Архивъ внутренней медицины, 2021
The European society of cardiology guideline for the diagnosis and treatment of acute and chronic heart failure (CHF) in 2016 identified a new group of patients with mid-range left ventricular ejection fraction (LVEF) with reference interval in the range
N. T. Vatutin, A. N. Shevelok, V. V. Venzheha   +2 more
doaj   +1 more source

Atmospheric Water Harvesting Through Polymer Hydrogel Sorbents: Materials Chemistry, Design Strategies, and Applications

Advanced Science, EarlyView.
Polymer‐based hydrogels have emerged as promising materials for atmospheric water harvesting (AWH) due to their high water affinity, tunable network structure, and excellent moisture adsorption‐desorption performance. Functional hydrogel systems enable efficient water capture and controlled release under low‐energy conditions, offering a sustainable ...
Swagata Datta, Sushmit Sen, Nilanjan Dey, Amrita Chatterjee, Ananya Sadhu, Sudipta Sarkar, Pradip K. Maji   +6 more
wiley   +1 more source

Pharmacological management of heart failure with reduced ejection fraction

, 2022
Heart failure with reduced ejection fraction is a disease with a high prevalence, cost, and mortality rate. However, in recent years, new diagnostic and management breakthroughs have been made, as well as new pharmacological and non-pharmacological ...
Oladunjoye, Kayode
core  

Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. [PDF]

, 2014
Heart failure is common in older people and its prevalence is increasing. The Heart 'omics' in AGEing (HOMAGE) project aims to provide a biomarker approach that will improve the early diagnosis of heart failure.
Rocca, Hans-Peter Brunner-La, Heymans, Stephane, Staessen, JA, Pocock, Stuart, Zannad, Faiez, Bauters, C, Brunner-La Rocca, Hans-Peter; id_orcid, Thijs, Lutgarde, Heymans, S, Cleland, J.G., Pocock, S, Staessen, Jan A., Mebazaa, A, Delles, C, Thijs, L, Masson, Serge, Bauters, Christophe, Kuznetsova, Tatiana, Tomaschitz, A, McDonald, K, Pinet, Florence, Collier, T, Mamas, Mamas, Pinet, F, Jacobs, Lotte, Mebazaa, Alexandre, Sever, P, Jin, Yu, Cleland, JG, Kuznetsova, T, Latini, Roberto, Rouet, P, Mamas, M, Cleland, John G F, Sever, Peter, Jin, Y, Latini, R, Delles, Christian, Rouet, Philippe, Brunner-La Rocca, Hans-Peter, Zannad, F, Brunner-La Rocca, HP, Jacobs, L, Pieske, Burket, Diez, Javier, Diez, J, Cleland, John GF, Masson, S, McDonald, Kenneth, Pieske, B, Staessen, Jan A, Cleland, John G.F., Rocca, HP, Collier, Timothy, Tomaschitz, Andreas, Pieske, Burkert   +55 more
core   +1 more source

SerpinA3 is an Endogenous TGF‐β Receptor Antagonist that Attenuates Cardiac Fibroblast Activation and Fibrotic Remodeling

Advanced Science, EarlyView.
SerpinA3 acts as an endogenous TGF‐β receptor antagonist that binds to the extracellular domain of TGFR‐1, thereby preventing TGFR‐1–TGFR‐2 complex formation. This receptor‐level blockade suppresses TGF‐β/Smad2/3 signaling, attenuates cardiac fibroblast activation, and extracellular matrix deposition, and ultimately alleviates pressure overload–induced
Hui Wang, Jieyu Cui, Chunlu Huang, Wanyi Guo, Tong Liu, Yi Zhu, Shuai Shao, Kangyin Chen, Jinlong He, Qiankun Bao   +9 more
wiley   +1 more source